Utama › Limfoma Sel B Besar Difus › Texas › Houston
Kajian klinikal Limfoma Sel B Besar Difus di Houston, TX
17 kajian untuk Limfoma Sel B Besar Difus sedang mencari peserta di lokasi dalam dan sekitar Houston (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Mengambil pesertaFasa 2
- MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Mengambil pesertaKajian pemerhatian
- Texas Children's Hospital, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Mengambil pesertaFasa 1/2
- Md Anderson Cancer Center, Houston
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Mengambil pesertaFasa 3
- Houston Methodist Cancer Center ( Site 0154), Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Mengambil pesertaFasa 1
- Baylor College of Medicine, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Mengambil pesertaFasa 1
- MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Mengambil pesertaFasa 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Mengambil pesertaFasa 1
- Md Anderson Cancer Center, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Mengambil pesertaFasa 1/2
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Mengambil pesertaFasa 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Mengambil pesertaFasa 3
- MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Mengambil pesertaFasa 1
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
Mengambil pesertaFasa 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Mengambil pesertaFasa 1
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Mengambil pesertaFasa 1
- MD Anderson Cancer Center, Houston
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Mengambil pesertaFasa 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
Mengambil pesertaFasa 1
- MD Anderson Cancer Center, Houston
Kajian Limfoma Sel B Besar Difus di bandar lain
- New York City, NY21 kajian
- Baldwin Park, CA19 kajian
- Chicago, IL18 kajian
- Los Angeles, CA17 kajian
- Boston, MA16 kajian
- Milwaukee, WI16 kajian
- Nashville, TN15 kajian
- Portland, OR15 kajian
- Philadelphia, PA15 kajian
- Durham, NC14 kajian
- Dallas, TX13 kajian
- Seattle, WA12 kajian
Kajian lain di Houston
- Kanser Paru-paru Bukan Sel Kecil145 kajian
- Kanser Payudara126 kajian
- Kanser (semua jenis)121 kajian
- Kanser Metastatik104 kajian
- Kanser Kolorektal102 kajian
- Kanser Ovari89 kajian
- Leukemia Mieloid Akut85 kajian
- Kanser Paru-paru78 kajian
- Kanser Prostat76 kajian
- Kanser Endometrium68 kajian
- Kanser Pankreas61 kajian
- Melanoma59 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.